Quest for the right Drug

|
עמוד הבית / פק-מרץ טבליות / מידע מעלון לרופא

פק-מרץ טבליות PK-MERZ TABS (AMANTADINE SULFATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות מצופות פילם : FILM COATED TABLETS

Special Warning : אזהרת שימוש

4.4     Special warnings and precautions for use
An ECG (50 mm/s) should be recorded before and 1 and 3 weeks after commencing treatment and the Bazett frequency-corrected QT time (QTc) determined manually. Such an ECG should also be recorded before and 2 weeks after any subsequent increase in dose. Further ECG check-ups should then take place at least once a year. Treatment must be avoided or discontinued in patients who show baseline QTc values above 420 ms, an increase in QTc of more than 60 ms during treatment with PK- Merz 100 mg film-coated tablets, or a QTc time in excess of 480 ms during treatment with PK-Merz 100 mg film-coated tablets, and in patients who show discernible U waves.
Patients at risk of electrolyte imbalances, owing e.g. to treatment with diuretics, frequent vomiting and/or diarrhoea, use of insulin in emergency situations or renal or anorectic conditions must undergo adequate monitoring of laboratory parameters and appropriate electrolyte replacement, particularly for potassium and magnesium.
In the event of symptoms such as palpitations, dizziness or syncope, treatment with PK-Merz 100 mg film-coated tablets must be immediately discontinued and the patient checked within 24 hours for QT prolongation. If no QT prolongation is present, treatment with PK-Merz 100 mg film-coated tablets can be recommenced, taking into account the contraindications and interactions.
In the case of patients with cardiac pacemakers, exact determination of QT times is not possible, therefore the decision on use of PK-Merz 100 mg film-coated tablets must be made on an individual basis in consultation with the patient’s cardiologist.
Supplementary administration of amantadine for the prevention and treatment of influenza virus A infection is inadvisable and should be avoided on account of the danger of overdose.
Yellow-orange lacquer (E 110) can trigger allergic reactions.
Lactose: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.


Special precautions for use:
Patients treated simultaneously with neuroleptic drugs and PK-Merz 100 mg film-coated tablets are at risk of developing life-threatening neuroleptic malignant syndrome if PK-Merz 100 mg film-coated tablets are discontinued abruptly.
Intoxication may occur in patients with renal impairment.
Particular caution is advisable when prescribing PK-Merz 100 mg film-coated tablets to patients with organic brain syndrome or to those who are prone to cerebral seizures, as seizures and intensification of individual symptoms may occur (see sections 4.2 and 4.8).
Patients with known cardiovascular conditions must remain under regular medical monitoring during treatment with PK-Merz 100 mg film-coated tablets.
Patients with Parkinson’s disease often exhibit disease symptoms such as low blood pressure, salivation, sweating, elevated body temperature, heat accumulation, fluid retention and depression. In such patients, due consideration should be given to the undesirable effects and interactions of PK- Merz 100 mg film-coated tablets.
The patient should be examined by an ophthalmologist as soon as symptoms such as loss of visual acuity or blurred vision occur, in order to rule out corneal oedema as a possible cause. PK-Merz 100 mg film-coated tablets should be discontinued if corneal oedema is diagnosed. Corneal oedema caused by PK-Merz 100 mg film-coated tablets is generally reversible within a month.
Patients should be asked to consult their doctor if they experience problems when passing urine.


Effects on Driving

4.7     Effects on ability to drive and use machines
Effects on vigilance and accommodation, particularly in association with the effects of other drugs used to treat parkinsonian syndromes, cannot be ruled out. At the beginning of treatment there may consequently be a further deterioration in the ability to drive and operate machinery over and above any impairment caused by the condition itself.
This impairment is further intensified in combination with alcohol.

שימוש לפי פנקס קופ''ח כללית 1994 Influenza type A virus, parkinsonism (idiopathic & postencephalitic), drug induced extrapyramidal reactions, symptomatic parkinsonism caused by carbon monoxide intoxication or cerebral arteriosclerosis in the elderly
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

MEGAPHARM LTD

רישום

137 43 27100 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

10.06.14 - עלון לרופא

עלון מידע לצרכן

10.06.14 - עלון לצרכן 21.01.14 - החמרה לעלון

לתרופה במאגר משרד הבריאות

פק-מרץ טבליות

קישורים נוספים

RxList WebMD Drugs.com